Destiny-Breast09 delivered something never seen before in first-line HER2-positive metastatic breast cancer — a median progression-free survival of over 40 months.
With higher response rates, deeper responses, and strong activity even in high-risk patients, this trial may redefine what frontline therapy looks like moving forward.
40-Month PFS: Why Destiny-Breast09 Is a Game Changer
You may also like
Recommended Videos
